Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Human Immunodeficiency Virus (HIV) Therapeutics Market

Human Immunodeficiency Virus (HIV) Therapeutics Market Trends

Report ID: GMI12601
Published Date: Dec 2024
Report Format: PDF

Download Free Sample

Human Immunodeficiency Virus Therapeutics Market Trends

The adoption of long-acting injectable HIV treatments, such as cabotegravir/rilpivirine, is increasing, offering monthly or bi-monthly dosing options. These therapies aim to enhance patient adherence and reduce the burden of daily oral medications. The success of long-acting injectables is driving a shift towards more convenient and patient-friendly treatment options.
Early diagnosis and the implementation of Pre-Exposure Prophylaxis (PrEP) are becoming critical strategies in HIV prevention. The increasing prescription of PrEP to high-risk individuals is significantly reducing new infection rates, especially in regions with high HIV prevalence.
Fixed-dose combination therapies, which combine multiple HIV drugs into a single pill, are gaining traction. These therapies streamline treatment regimens and enhance patient adherence, thereby strengthening their role in HIV management.
AI and digital health tools are increasingly being utilized to monitor and manage HIV treatment. These technologies assist in forecasting treatment outcomes, monitoring patient adherence, and delivering real-time data to healthcare professionals.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global HIV therapeutics industry was valued at USD 39 billion in 2024 and is projected to grow at a 3.5% CAGR from 2025 to 2034, driven by the high incidence of HIV infections and advancements in therapeutic treatments.

Branded drugs held a 74.5% market share in 2024, supported by increasing prescriptions for fixed-dose combinations like Biktarvy, Genvoya, and Triumeq.

The U.S. led the North American HIV therapeutics market with a revenue of approximately USD 14.5 billion in 2024, driven by increased PrEP prescriptions and expanded HIV testing.

Key players in the market include AbbVie, Aurobindo Pharma, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla, Dr. Reddy's Laboratories, F. Hoffmann-La Roche, Gilead Sciences, Hetero Drugs, and Johnson & Johnson.